Fate Therapeutics (FATE) Treasury Shares (2012 - 2026)

Fate Therapeutics has reported Treasury Shares for 15 years, with the latest figure at $9.3 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 28.42% year-over-year to $9.3 million; the trailing twelve-month figure through Mar 2026 stood at $9.3 million (up 28.42% YoY), and the FY2025 full-year result was $6.6 million, up 6.79% from the prior year.
• Treasury Shares for Q1 2026 stood at $9.3 million, up from $6.6 million in the prior quarter.
• The five-year high for Treasury Shares was $9.3 million in Q1 2026, with the low at $3.1 million in Q4 2023.
• Historically, Treasury Shares has averaged $5.5 million across 5 years, with a median of $5.9 million in 2022.
• Annual changes were most pronounced in 2022 — Treasury Shares surged 284.99% — and 2023, when it plunged 47.72%.
• Fate Therapeutics' Treasury Shares stood at $5.9 million in 2022, then sank by 47.72% to $3.1 million in 2023, then surged by 102.74% to $6.2 million in 2024, then grew by 6.79% to $6.6 million in 2025, then surged by 40.02% to $9.3 million in 2026.
• The last three Treasury Shares figures came in at $9.3 million (Q1 2026), $6.6 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.